See the 20-slide presentation this biotech startup used to raise $75 million for a way to treat blindness with CRISPR

SparingVision, a Paris-based startup, is developing gene-editing therapies for eye diseases with the CRISPR biotech Intellia Therapeutics.

Leave a Comment

Your email address will not be published.